- Experience. Mayo Clinic is a leader in the treatment of polycystic kidney disease. Each year doctors at the three Mayo Clinic locations care for about a 1,000 patients who have polycystic kidney disease.
Pediatric expertise. Mayo Clinic in Minnesota offers diagnosis, care and treatment in a child-friendly environment for children who have autosomal recessive polycystic kidney disease (ARPKD) or complications of autosomal dominant polycystic kidney disease.
In Mayo's efficient system, your child can see multiple specialists and receive testing and treatment in days, not months. The care team also includes nurse specialists, social workers, dietitians and behavioral health specialists.
- Team approach. Mayo Clinic kidney specialists (nephrologists) and other doctors experienced in diagnosing and treating polycystic kidney disease — such as hypertension specialists and geneticists — work together to develop a treatment plan that meets your needs. Mayo doctors also collaborate with research scientists to find new approaches.
Novel treatments. Mayo Clinic is at the forefront of research into medications and therapies for managing polycystic kidney disease. Mayo Clinic researchers have discovered many of the genes that cause different forms of polycystic kidney disease.
This ongoing research means that in addition to standard therapies, you may also have access to new or emerging polycystic kidney disease therapies not available elsewhere.
- Renowned transplant program. If you require a kidney transplant, you'll receive a timely referral to transplant specialists at Mayo Clinic's kidney transplant program.
Mayo Clinic in Rochester, Minn., ranks No. 1 for kidney disorders in the U.S. News & World Report Best Hospitals rankings. Mayo Clinic in Scottsdale, Ariz., ranks among the Best Hospitals for kidney disorders by U.S. News & World Report. Mayo Clinic in Jacksonville, Fla., is ranked high performing for kidney disorders by U.S. News & World Report.
June 14, 2014
- Polycystic kidney disease. National Kidney and Urologic Diseases Information Clearinghouse. http://kidney.niddk.nih.gov/kudiseases/pubs/polycystic/. Accessed March 29, 2014.
- Ferri FF. Ferri's Clinical Advisor 2014: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2014. https://www.clinicalkey.com. Accessed March 29, 2014.
- Alpern RJ, et al. Seldin and Giebisch's The Kidney. 5th ed. Philadelphia, Pa.: Elsevier; 2013. http://www.clinicalkey.com. Accessed March 29, 2014.
- Polycystic kidney disease. Kidney Foundation. http://www.kidney.org/atoz/content/polycystic.cfm . Accessed March 29, 2014.
- Taal MW, et al. Brenner & Rector's The Kidney. 9th ed. Philadelphia, Pa.: Saunders Elsevier; 2011. http://www.clinicalkey.com. Accessed March 29, 2014.
- Riggin EA. Decision Support System. Mayo Clinic, Rochester, Minn. Feb. 26, 2014.
- Devuyst O, et al. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Current Opinion in Nephrology and Hypertension. 2013;22:459.
- Rossetti S, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. Journal of the American Society of Nephrology. 2012;23:915.
- Torres VE, et al. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. Journal of the American Society of Nephrology. 2014; 25:18.
- Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine. 2012;367:2407.
- Hogan MC, et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrology Dialysis Transplantation. 2012;27:3532.
- Castle EP (expert opinion). Mayo Clinic, Phoenix /Scottsdale, Ariz. April 6, 2014.
- Heilman RL (expert opinion). Mayo Clinic, Phoenix/Scottsdale, Ariz. April 7, 2014.